Corporate Banner
Satellite Banner
Scientific Communities
Become a Member | Sign in
Home>News>This Article

Sigma-Aldrich® Receives National Institutes of Health Funding for Cardiovascular Disease Research

Published: Monday, August 09, 2010
Last Updated: Monday, August 09, 2010
Bookmark and Share
Sigma® Life Science to analyze plasma samples from FHS in researching novel biomarkers for cardiovascular disease.

Sigma-Aldrich® announced it has entered into an agreement with the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health, and Boston University (BU) to develop methods to measure several potential biomarkers of atherosclerotic cardiovascular disease (CVD) using plasma samples from the NHLBI’s Framingham Heart Study (FHS), one of the most prestigious clinical studies in medicine. Funding for the project is provided by the NHLBI to Sigma-Aldrich under a research subaward agreement with BU.

The FHS began in 1948 as a study of more than 5,000 residents of Framingham, Massachusetts, to identify the factors that increase the risk for CVD. Since then, it has expanded to include over 14,000 participants from three generations within families. Using the results of FHS, researchers have identified a host of risk factors, including high blood cholesterol levels, elevated blood pressure, smoking, diabetes and obesity. The FHS is funded by the NHLBI and conducted in collaboration with BU's School of Medicine and School of Public Health.

Sigma® Life Science, a biological products and services business of Sigma-Aldrich, plans to work with NHLBI and BU to provide for the analysis of plasma samples from 7,000 participants to investigate 180 potential biomarkers for CVD. Over the course of this five-year project, Sigma Life Science expects to develop antibody reagents for each identified target biomarker and incorporate the reagents into a multiplexed, high-throughput platform to measure the proteins of interest.

“Through this project, Sigma Life Science, the NHLBI and BU are furthering insight into a number of important CVD targets,” said Dave Smoller, President of Sigma-Aldrich’s Research Biotech Business Unit.”

Smoller  continues, “By embarking on this exciting effort, we believe we will help to develop the next generation of biomarker technologies for life science research and therapeutic applications, and provide greater understanding into the genetics and biological pathways of heart disease. The project is expected to facilitate the development of diagnostic tools for the early detection and prevention of CVD, as well as therapies for early treatment. We are hopeful that establishing valid surrogate biomarkers will also be useful in the development of more individualized treatments for patients. ”

The new project is part of a major FHS initiative called the Systems Approach to Biomarker Research in Cardiovascular Disease (SABRe CVD), which expects to identify and validate new CVD biomarkers, which in turn could ultimately lead to the development of blood tests to identify individuals at high risk of heart disease and stroke.

Only information from FHS participants who have consented to sharing their specimens and data for genetic research will be used, and no shared information will be attributed to a specific participant to protect participants' privacy. Data from these studies will be accessible to other scientists through dbGAP (Database for Genotype and Phenotype), in accordance with data-sharing policies.

“We believe this research will accelerate the development of new diagnostics and treatments for common life-threatening conditions,” said Karen Antman, M.D., Dean of Boston University School of Medicine. “Our faculty takes great pride in being part of this exciting research which may improve the lives of millions of people globally for the better,” she added.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,600+ scientific posters on ePosters
  • More Than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

SAFC Completes Manufacturing Expansion in St. Louis
Expansion to support commercial-scale antibody drug conjugate (ADC) manufacturing.
Saturday, May 16, 2015
SAFC Expands Carlsbad, Calif. Facility
Expansion to support commercial-scale gene therapy production, testing and filling.
Saturday, May 16, 2015
Sigma-Aldrich Expands in Singapore
New State-of-the-Art Technical Center, cGMP Distribution Center and Headquarters enhances ability to support customers in the region.
Monday, April 20, 2015
Sigma-Aldrich & Roche Enter Exclusive Distribution Agreement
Provides researchers with global access to Roche biochemical reagents product portfolio.
Thursday, March 19, 2015
Sigma and Czech Center for Phenogenomics Collaborate
Sigma-Aldrich® and the Institute of Molecular Genetics, Czech Center for Phenogenomics, establish CRISPR core lab collaboration.
Friday, January 30, 2015
SAFC’s Dry Powder Media Manufacturing Facility in Irvine, Scotland
Officially opens following extensive validation process.
Friday, January 23, 2015
Sigma-Aldrich Licenses Foundational CRISPR Patents from Broad Institute
Company is able to make, use and distribute the advanced gene editing tools for numerous research applications.
Tuesday, December 09, 2014
Sigma-Aldrich to Restructure Business into Three New Units
Sigma-Aldrich has provided the first details of a major restructuring that will align its organisation into three customer and market-focused business units.
Thursday, November 22, 2012
SAGE® Labs, Ekam Imaging, Inc. Partner on Preclinical Imaging Assays
Companies to develop a suite of preclinical services based on the advanced translational power of genetically engineered rat models from SAGE Labs and Ekam's expertise in functional magnetic resonance imaging (fMRI) technology.
Friday, October 19, 2012
Sigma-Aldrich to Acquire BioReliance
Sigma-Aldrich Corporation has signed an agreement to acquire BioReliance Holdings, Inc. from Avista Capital Partners for $350 million in cash.
Tuesday, January 10, 2012
Biotech firm inks deal with Sigma-Aldrich
Henrietta-based biotechnology company Diffinity Genomics Inc. has inked a non-exclusive global distribution deal with Sigma-Aldrich Co. LLC, the local company said.
Wednesday, November 30, 2011
Hydrogen Storage Collaboration Between Sigma-Aldrich and Ilika Technologies to Scale-up and Commercialize Boron Hydride Materials
Materials show promise as high energy, low pressure hydrogen source.
Monday, July 25, 2011
Domainex Collaborates with Sigma-Aldrich to Advance the Study of Epigenetic Proteins Involved in Cancer and Stem Cell Biology
Domainex Ltd., have announced a collaboration with Sigma-Aldrich that will provide essential tools, including biochemical assays and monoclonal antibodies, for the study of proteins involved in the rapidly developing field of epigenetics.
Monday, November 15, 2010
Sigma® Life Science to Supply Oligonucleotides to Research Councils UK
A three-year contract with RCUK Shared Services Centre Limited to be a preferred supplier for synthetic oligonucleotides.
Monday, September 20, 2010
Sigma-Aldrich to Host Molecular Self-Assembly Webcast
November 17 Webcast Features MSA Scientific Leaders Professor Paul Weiss and Professor Milan Mrksich
Wednesday, November 11, 2009
Scientific News
Researchers Develop Classification Model for Cancers Caused by KRAS
Most frequently mutated cancer gene help oncologists choose more effective cancer therapies.
Fixing Holes in the Heart Without Invasive Surgery
UV-light enabled catheter is a medical device which represents a major shift in how cardiac defects are repaired.
Chromosomal Chaos
Penn study forms basis for future precision medicine approaches for Sezary syndrome
Enzyme Malfunction May be Why Binge Drinking Can Lead to Alcoholism
A new study in mice shows that restoring the synthesis of a key brain chemical tied to inhibiting addictive behavior may help prevent alcohol cravings following binge drinking.
Key to Natural Detoxifier’s Reactivity Discovered
Results have implications for health, drug design and chemical synthesis.
New Treatment for Obesity Developed
Researchers at the University of Liverpool, working with a global healthcare company, have helped develop a new treatment for obesity.
New Protein Found in Immune Cells
Immunobiologists from the University of Freiburg discover Kidins220/ARMS in B cells and demonstrate its functions.
Will Brain Palpation Soon Be Possible?
Researchers have developed non-invasive brain imaging technique which provides the same information as physical palpation.
Shaking Up the Foundations of Epigenetics
Researchers at the Centre for Genomic Regulation (CRG) and the University of Barcelona (UB) published a study that challenges some of the current beliefs about epigenetics.
Groundbreaking Computer Program Diagnoses Cancer in Two Days
Researchers have combined genetics with computer science and created a new diagnostic technology can with 85 per cent certainty identify the source of the disease and thus target treatment and, ultimately, improve the prognosis for the patient.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,600+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos